INCYTE CORP 4

EVP & Chief Scientific Officer Patrick A. Mayes exercised multiple stock options in Incyte Corp (INCY) and sold nearly all of the resulting common shares, for total sales of roughly $5.4 million while retaining about 61,441 shares and significant unvested RSUs.

On this Form 4, Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp, reported a series of option exercises and related stock sales. On July 31, 2026 he exercised multiple employee stock options into an aggregate of approximately 39,976 shares of common stock at strike prices ranging from about $61 to $106 per share, then sold roughly 39,653 shares on the same day at market prices clustered around $119–$122 per share, generating proceeds of about $4.7 million while modestly increasing his direct holdings. On August 3, 2026 he exercised an additional 6,055 options at $105.43 and sold the same 6,055 shares at $120.43, adding roughly another $0.7 million in sale value but leaving his direct ownership at 61,441 shares, plus 59,537 unvested RSUs. The pattern and footnotes indicate these are largely routine option exercises tied to vesting schedules, combined with liquidity sales rather than a net build in open‑market holdings.

Filing Facts

CIK

879169

Ticker

INCY

Form

4

Source Type

fda

Accession

0002079962-26-000013

Alert Tier

6